Publication Name	World Journal of Gastroenterology
Manuscript ID	3926
Country	China

Received	2013-06-02 22:24
Peer-Review Started	2013-06-02 22:39
To Make the First Decision	2013-07-11 08:38
Return for Revision	2013-07-12 09:11
Revised	2013-08-01 15:27
Second Decision	2013-08-13 11:57
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-08-13 13:59
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-09-04 14:32
Publish the Manuscript Online	2013-09-21 09:08

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Phase Ⅱ study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma
Manuscript Source	Invited Manuscript
All Author List	Yi-Fu He, Chu-Shu Ji, Bing Hu, Ping-Sheng Fan, Chang-Lu Hu, Feng-Shou Jiang, Jian Chen, Lei Zhu, Yi-Wei Yao and Wei Wang
Funding Agency and Grant Number	Funding Agency Grant Number Natural Science Foundation of Anhui Province, China 070413256X Medical Research Foundation of Anhui Provincial Health Department 2010B001 Medical Research Foundation of Anhui Provincial Health Department 13zc012
Corresponding Author	Bing Hu, Professor, Department of Medical Oncology, Anhui Provincial Hospital affliated to Anhui Medical University, 17 Lujiang Road , Hefei 230001, Anhui Province, China. hubing3756@hotmail.com
Key Words	Esophageal squamous cell cancer; Front-line chemotherapy; Paclitaxel; Nedaplatin
Core Tip	Esophageal cancers are among the most aggressive tumors with a poor prognosis. Till now, there has been no standard chemotherapy regimen for advanced esophageal cancer. In this paper, we conducted a phase Ⅱ study on combination chemotherapy consisting of paclitaxel and nedaplatin in previously untreated patients with metastatic esophageal squamous cell carcinoma (ESCC). Our results demonstrated that the combination of two drugs is active and well tolerated as a first-line therapy for patients with recurrent or metastatic ESCC.
Publish Date	2013-09-21 09:08
Citation	He YF, Ji CS, Hu B, Fan PS, Hu CL, Jiang FS, Chen J, Zhu L, Yao YW, Wang W. A phase Ⅱ study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol 2013; 19(35): 5910-5916
URL	http://www.wjgnet.com/1007-9327/full/v19/i35/5910.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i35.5910

Full Article (PDF)	WJG-19-5910.pdf
Manuscript File	3926-Review.doc
Answering Reviewers	3926-Answering Reviewers.pdf
Copyright License Agreement	3926-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	3926-Language certificate.PDF
Peer-review Report	3926-Peer review.pdf
Scientific Editor Work List	3926-Scientific editor work list.doc